mab
indispens
health
also
prevent
food
poison
use
investig
environment
pollut
howev
despit
widespread
distribut
signific
peopl
never
heard
mab
transform
healthcar
spawn
entir
new
industri
produc
laboratori
mab
deriv
billion
tini
antibodi
made
everi
day
immun
system
combat
substanc
known
antigen
regard
foreign
potenti
danger
million
differ
type
antibodi
found
blood
human
mammal
made
white
blood
cell
known
b
lymphocyt
antibodi
highli
specificthat
abil
bind
one
particular
antigen
may
deriv
bacteria
virus
fungi
parasit
pollen
nonliv
substanc
toxin
chemic
drug
foreign
particl
consid
alien
bodi
antibodi
mark
antigen
type
cell
produc
immun
system
attack
field
genet
engin
therapeut
mab
reli
mani
invent
decad
research
two
key
discoveri
stand
semin
event
laid
groundwork
field
exist
know
today
although
mab
first
describ
kohler
milstein
origin
rodent
form
replac
human
equival
potenti
therapeut
agent
began
properli
appreci
lonberg
winter
et
al
reason
complex
relat
combin
percept
includ
patent
immunogen
effector
function
wish
avoid
undesir
side
effect
increas
scientif
interest
mab
clearli
seen
fig
show
rise
number
publish
articl
use
keyword
monoclon
antibodi
differ
databas
pubm
scopu
athough
fewer
publish
articl
number
public
constant
year
scienc
direct
wiley
gener
introduct
mab
use
drug
treat
variou
diseas
also
use
power
tool
wide
rang
medic
applic
routin
use
hospit
blood
type
tissu
vital
process
ensur
safe
blood
transfus
organ
transplant
case
employ
research
probe
determin
patholog
pathway
caus
diseas
cancer
autoimmun
diseas
neurolog
disord
diagnost
front
monoclon
antibodi
intrins
compon
test
kit
detect
ovul
pregnanc
menopaus
also
use
analyz
bodi
fluid
medic
diagnosi
determin
whether
heart
attack
unlik
polyclon
antibodi
mab
ident
antibodi
produc
one
type
immun
cell
use
current
hybridoma
mousehuman
hybrid
cell
technolog
origin
develop
georg
kohler
cesar
milstein
neil
jern
mab
produc
bind
tightli
virtual
materi
antigen
defin
substanc
prompt
gener
antibodi
specif
bind
antigen
typic
consist
protein
polysaccharid
epitop
also
known
antigen
determin
part
antigen
actual
bind
antibodi
occur
mab
technolog
allow
scientist
produc
huge
quantiti
pure
antibodi
aim
specif
select
target
lead
design
new
diagnost
test
therapeut
inject
payload
mab
bloodstream
antibodi
head
straight
diseas
target
today
growth
profit
mab
outstrip
earlier
type
biotechnolog
drug
tradit
pharmaceut
one
inde
expans
among
fastest
global
pharmaceut
world
part
reflect
sector
embrac
mab
answer
dwindl
drug
pipelin
reduc
revenu
stream
face
expir
key
patent
growth
gener
medicin
drug
base
mab
technolog
name
end
mab
first
drug
receiv
food
drug
administr
fda
approv
rituxan
rituximab
fig
treatment
nonhodgkin
lymphoma
develop
idec
sinc
merg
biogen
rituximab
mab
protein
primarili
found
surfac
immun
system
b
cell
rituximab
destroy
b
cell
therefor
use
treat
diseas
character
excess
number
b
cell
overact
b
cell
dysfunct
b
cell
includ
mani
lymphoma
leukemia
transplant
reject
autoimmun
disord
idec
team
genentech
get
fda
approv
comarket
rituxan
parallel
genentech
develop
herceptin
trastuzumab
treatment
breast
cancer
associ
receptor
herceptin
approv
fda
first
import
exampl
person
medicin
requir
diagnost
test
ensur
efficaci
sinc
patient
express
gene
breast
cancer
tissu
chanc
benefit
treatment
mab
today
six
therapeut
mab
among
bestsel
drug
world
estim
global
sale
success
mab
worth
billion
among
adalimumab
humira
use
treatment
rheumatoid
arthriti
autoimmun
diseas
top
sell
drug
list
across
world
reach
annual
incom
million
thu
mab
sale
expect
higher
lipitor
use
cholesterol
reduct
largest
prescrib
drug
histor
king
sinc
methodolog
avail
gener
mab
dramat
evolv
hybridoma
technolog
use
produc
murin
mab
kohler
milstein
sophist
recombin
engin
technolog
et
al
b
steinitz
et
al
appropri
design
specif
mab
choic
thu
produc
human
chimer
complet
fulli
human
mab
fig
et
al
b
jone
et
al
lonberg
riechmann
et
al
novel
method
major
consequ
develop
clinic
applic
mab
diseas
target
immunogen
safeti
mab
substanti
limit
antibodi
produc
hybridoma
technolog
could
overcom
mab
antigen
specif
desir
physicochem
properti
could
develop
highscal
product
mab
industri
level
could
achiev
spark
race
develop
antibodymedi
therapeut
clinic
invest
larg
amount
money
biopharmaceut
sector
toward
end
alreadi
pay
major
success
human
mab
immun
inflammatori
condit
rheumatoid
arthriti
ra
crohn
diseas
ulcer
coliti
spondyloarthropathi
juvenil
arthriti
psoriasi
psoriat
arthriti
other
andreako
et
al
mark
mere
begin
rapidli
evolv
field
divers
mab
current
evalu
clinic
trial
candid
approv
fda
usa
scale
mab
product
therapeut
pose
sever
challeng
major
issu
produc
high
quantiti
drug
reason
cost
cell
line
yield
half
gram
mab
per
liter
product
time
consum
expens
ideal
develop
figur
monoclon
antibodi
rituximab
antibodydrug
conjug
hybrid
cell
line
could
produc
g
mab
per
liter
demand
sever
step
even
requir
skill
patienc
first
creation
hybrid
cell
clone
secret
mab
high
concentr
select
cultur
medium
develop
encourag
optim
growth
hybridoma
scale
media
easi
term
qualiti
control
contain
fifti
ingredi
import
determin
mani
nutrient
add
hybridoma
stop
secret
mab
exampl
given
much
glucos
antibodydrug
conjug
adc
mab
bear
cytotox
drug
coval
bound
via
chemic
linker
defin
prodrug
prodrug
inact
less
activ
deriv
drug
molecul
undergo
enzymat
chemic
transform
regener
activ
form
adc
design
superior
either
antibodi
therapeut
chemotherapi
alon
overcom
limit
preserv
merit
antibodi
connect
cytotox
warhead
drug
via
linker
serv
target
deliveri
system
tumor
express
antigentarget
recogn
antibodi
ideal
blood
system
administr
prodrug
nontox
upon
bind
antibodi
target
tumor
antigen
intern
complex
cancer
cell
drug
releas
activ
form
suffici
quantiti
kill
cell
top
care
choic
targetantigen
express
specif
tumor
indic
requir
find
best
combin
antibodi
linker
drug
besid
characterist
constraint
link
impact
bander
combin
nanoparticl
antibodi
offer
versatil
togeth
specif
fig
allow
huge
potenti
market
targetantigen
start
point
build
adc
first
determin
tumor
indic
target
adc
potenti
impact
choic
conjug
drug
addit
target
also
drive
criteria
defin
select
target
patient
popul
within
tumor
indic
mab
typic
suscept
noncoval
aggreg
upon
storag
aggreg
driven
minim
free
energi
achiev
antibodi
come
close
contactfor
instanc
rel
hydrophob
site
molecul
dimer
may
thought
first
step
aggreg
sometim
process
proce
dimer
mayb
revers
moor
et
al
growth
lead
larger
larger
oligom
even
potenti
insolubl
particul
time
progress
wang
et
al
adc
decor
one
small
molecul
drug
moieti
differ
set
biophys
properti
compar
unconjug
antibodi
lead
new
alter
intermolecular
interact
antibodi
exhibit
accept
figur
conjug
nanoparticl
antibodi
advantag
antibodydrug
conjug
aggreg
behavior
unconjug
form
may
differ
physic
behavior
conjug
form
either
chang
surfac
properti
hydrophob
due
drug
attach
drug
alter
higherord
structur
antibodi
new
mode
antibodyantibodi
interact
possibl
factor
could
contribut
substanti
differ
propens
aggreg
effect
readili
observ
formul
screen
design
test
conjug
unconjug
form
parallel
subject
assay
studi
automat
reveal
exact
caus
effect
relat
conjug
form
conjug
process
degre
molecul
physic
alter
conjug
may
assess
techniqu
differenti
scan
calorimetri
dsc
wakankar
et
al
physic
perturb
manifest
chang
like
decreas
onset
melt
melt
temperatur
tm
conjug
mab
compar
unconjug
antibodi
decreas
thermodynam
stabil
may
translat
decreas
colloid
stabil
conjug
compar
unconjug
antibodi
part
adc
chemic
stabil
inherit
unconjug
antibodi
instanc
unconjug
antibodi
suscept
deamid
isomer
known
ph
depend
degrad
mode
also
like
present
adc
type
degrad
may
impact
product
potenc
especi
affect
residu
found
complementaritydetermin
region
much
learn
year
experi
unconjug
antibodi
suscept
variou
amino
acid
residu
chemic
degrad
allow
substanti
insight
gain
examin
protein
primari
sequenc
alon
coupl
avail
inform
local
solvent
exposur
flexibl
koski
et
al
robinson
robinson
may
expect
chemic
modif
primari
sequenc
unconjug
antibodi
also
occur
adc
form
fragment
anoth
possibl
chemic
degrad
pathway
adc
driven
breakag
coval
bond
chain
within
peptid
backbon
alter
physic
state
molecul
follow
addit
small
molecul
drug
may
result
differ
suscept
adc
fragment
fundament
suscept
adc
fragment
like
deriv
mostli
mab
common
unconjug
antibodi
degrad
mode
involv
break
heavi
chain
peptid
near
hing
region
lead
free
fab
fab
fc
product
cordoba
et
al
still
feasibl
degrad
pathway
adc
well
comparison
fragment
rate
conjug
unconjug
antibodi
reveal
whether
adc
form
differ
stabil
toward
fragment
coval
bond
link
drug
antibodi
may
broken
varieti
mechan
shelf
life
product
stress
storag
condit
formul
develop
adc
aim
ensur
stabl
highqual
product
dose
patient
though
goal
common
pharmaceut
formul
adc
present
uniqu
set
physicochem
properti
impact
safeti
qualiti
efficaci
compar
tradit
therapeut
protein
although
bodi
literatur
outlin
product
attribut
affect
safeti
qualiti
efficaci
convent
unconjug
mab
goetz
et
al
understand
attribut
import
adc
emerg
choic
formul
potenti
affect
categori
adc
qualiti
attribut
conjug
adc
requir
unconjug
antibodi
intermedi
formul
develop
process
conjug
necessarili
involv
formul
mab
stage
like
intermedi
manufactur
final
adc
form
formul
optim
antibodi
portion
adc
follow
similar
cours
unconjug
antibodi
therefor
leverag
biotechnolog
industri
consider
experi
develop
class
molecul
mani
exampl
success
commerci
antibodi
formul
liquid
lyophil
report
wang
et
al
howev
complex
formulationdevelop
process
potenti
increas
qualiti
attribut
small
molecul
drug
conjug
form
taken
account
antibodyconjug
nanoparticl
use
princip
two
biomed
applic
diagnosi
therapi
therapi
develop
target
drug
deliveri
repres
togeth
tissu
repair
main
applic
antibodyconjug
nanoparticl
diagnosi
applic
divid
use
vivo
use
vitro
experiment
includ
contrast
agent
magnet
reson
imag
mri
sens
cell
sort
biosepar
enzym
immobil
immunoassay
transfect
gene
deliveri
purif
today
one
interest
challeng
pose
drugdeliveri
system
develop
smart
vector
requir
safe
easili
administ
econom
allow
simultan
diagnosi
treatment
moreov
intend
deliveri
precis
control
term
dose
site
action
reduc
advers
side
effect
regard
mani
import
siteselect
drug
highli
toxic
antitumor
molecul
must
reach
target
cell
tissu
without
releas
nanosci
nanotechnolog
found
way
field
biotechnolog
medicin
nanosci
studi
structur
materi
atom
molecular
scale
level
rang
usual
nm
nanoparticl
offer
specif
physicochem
properti
exhibit
bulk
form
materi
show
constant
physic
properti
regardless
size
antibodi
nanos
biolog
product
part
specif
immun
system
addit
properti
pathogen
toxin
neutral
well
recruit
immun
element
complement
improv
phagocytosi
cytotox
antibodi
depend
natur
killer
cell
etc
could
carri
sever
element
toxin
drug
fluorochrom
even
nanoparticl
etc
use
sever
diagnost
procedur
even
therapi
destroy
specif
target
conjug
antibodi
nanoparticl
gener
product
combin
properti
sinc
properti
materi
differ
significantli
atom
subatom
level
larger
scale
nanomateri
attract
attent
research
pharmaceut
applic
especi
area
drug
deliveri
technolog
overcom
drawback
larges
materi
poor
bioavail
vivo
stabil
solubl
intestin
absorpt
sustain
target
deliveri
site
action
gener
side
effect
among
other
regard
nanostructur
report
protect
drug
degrad
gastrointestin
tract
even
provid
mean
bypass
liver
prevent
first
pass
metabol
technolog
also
abil
target
deliveri
drug
variou
area
bodi
enabl
deliveri
drug
poorli
watersolubl
moreov
nanotechnolog
improv
drug
bioavail
allow
remain
circul
blood
long
time
control
releas
nanostructur
also
abl
penetr
tissu
easili
taken
cell
allow
effici
deliveri
drug
target
site
action
nanostructur
report
taken
cell
rate
time
greater
microparticl
nanotechnolog
improv
perform
accept
dosag
form
even
may
enhanc
perform
drug
fail
clinic
trial
phase
nanotechnolog
definit
revolution
scienc
drug
deliveri
help
overcom
major
challeng
convent
drug
use
treatment
manag
chronic
diseas
cancer
asthma
hypertens
hiv
diabet
context
nanomedicin
defin
medic
applic
nanotechnolog
involv
research
diagnost
therapeut
applic
relat
nanotechnolog
nanotechnolog
appli
medicin
develop
strategi
manag
treat
even
cure
virtual
everi
type
human
diseas
mab
success
drug
also
power
tool
wide
rang
medic
applic
regard
last
year
sever
nanotechnolog
platform
medic
applic
converg
upon
special
toward
diagnosi
therapi
even
case
magnet
nanoparticl
studi
nanosci
optim
technolog
adc
nanocarri
driven
design
methodolog
tailor
address
specif
diseas
medic
anomali
adc
exampl
repres
excel
nanoscalebas
drug
deliveri
vehicl
thu
tend
focus
deliveri
certain
drug
treatment
cancer
conjug
differ
moieti
nanoparticl
widen
applic
field
provid
new
enhanc
properti
rang
biomoieti
conjug
nanoparticl
includ
low
molecular
weight
ligand
folic
acid
thiamin
dimercaptosuccin
acid
peptid
rgd
lhrd
antigen
peptid
intern
peptid
protein
bsa
transferrin
antibodi
lectin
cytokin
fibrinogen
thrombin
polysaccharid
hyaluron
acid
chitosan
dextran
oligosaccharid
heparin
polyunsatur
fatti
acid
palmit
acid
phospholipid
dna
plasmid
nanotempl
provid
uniqu
access
extrem
highthroughput
capabl
rapidli
defin
presenc
biomark
thu
lend
excel
platform
diagnost
applic
rapid
progress
made
drive
advanc
nanomedicin
especi
area
cancer
treatment
although
still
infanc
compar
medic
technolog
nanomedicin
undoubtedli
stay
enorm
impact
futur
health
wellb
man
nanocarri
nanometers
materi
capac
deliv
therapeut
agent
diseas
site
aria
schroeder
et
al
design
possess
uniqu
physicochem
properti
aim
improv
pharmacokinet
biodistribut
drug
molecul
li
huang
deliv
signific
amount
drug
molecul
exampl
therapeut
nanocarri
lipidbas
particl
aljam
kostarelo
micel
kedar
et
al
nanoparticl
shi
et
al
dendrim
svenson
polymersom
levin
et
al
propos
treatment
variou
diseas
includ
cancer
dhar
et
al
coronari
arteri
diseas
chan
et
al
rheumatoid
arthriti
thoma
et
al
particular
case
cancer
uniqu
anatomythat
leaki
tumor
vasculaturesconced
passiv
transport
nanocarri
enhanc
permeabl
retent
epr
effect
maeda
et
al
howev
poros
tumor
blood
vessel
may
vari
tumor
type
bae
even
success
deliveri
epr
effect
nanocarri
must
abl
intern
cancer
cell
gradishar
et
al
new
paradigm
drug
deliveri
embroil
combin
activ
passiv
target
target
ligand
antibodi
mamot
et
al
peptid
srinivasan
et
al
small
molecul
kukowskalatallo
et
al
aptam
farokhzad
et
al
attach
onto
surfac
nanocarri
carrier
recogn
bind
cellsurfac
receptor
subsequ
taken
cell
via
receptormedi
endocytosi
releas
therapeut
payload
shi
et
al
bind
affin
target
nanocarri
also
increas
sever
order
magnitud
multival
effect
among
target
ligand
antibodi
well
known
high
bind
affin
specif
avail
number
diseas
biomark
manjappa
et
al
antibodi
simpli
absorb
surfac
nanocarri
via
hydrophob
andor
electrostat
interact
sokolov
et
al
howev
use
approach
absorb
antibodi
may
orient
randomli
surfac
result
lose
bind
affin
furthermor
antibodi
may
exchang
endogen
protein
vivo
nob
et
al
therefor
antibodi
gener
prefer
attach
nanocarri
coval
arruebo
et
al
antibodi
consist
number
function
group
provid
mani
option
bioconjug
manjappa
et
al
bioconjug
take
place
mean
adsorpt
isoelectr
point
antibodi
via
electrostat
interact
direct
coval
linkag
surfac
nanoparticl
antibodi
use
adapt
molecul
use
adapt
molecul
gener
involv
streptavidin
biotin
format
complex
biotinlabel
polyclon
goat
antiescherichia
coli
antibodi
attach
streptavidinco
magnet
nanoparticl
use
separ
select
quantif
escherichia
coli
ground
beef
presenc
bacteria
varshney
et
al
mab
capabl
specif
recogn
bind
mani
molecul
mainli
protein
natur
capabl
wide
use
field
diagnosi
detect
hormon
vitamin
cytokin
allergen
numer
tumor
marker
wide
rang
marker
associ
mani
diseas
includ
microbi
infect
properti
mab
substanc
commonli
use
field
clinic
diagnosi
identifi
marker
therapeut
target
besid
applic
diseas
diagnosi
drug
discoveri
therapeut
applic
includ
mab
vehicl
carrier
drug
current
major
therapeut
applic
mab
includ
cancer
chronic
inflammatori
diseas
infect
constitut
largest
fastest
grow
sector
biolog
pharmaceut
industri
addit
offer
host
new
drug
fight
diseas
mab
provid
mean
monitor
patient
respons
therapi
help
lead
way
person
medicin
mab
market
cancer
autoimmun
disord
also
rang
diseas
includ
allerg
condit
asthma
agerel
macular
degener
eye
disord
multipl
sclerosi
neurolog
disord
osteoporosi
brittl
bone
also
investig
central
nervou
system
disord
alzheim
diseas
degen
brain
diseas
metabol
diseas
diabet
prevent
migrain
mab
use
therapeut
purpos
may
bind
varieti
antigen
present
surfac
tumor
cancer
cell
may
also
util
deliv
number
differ
type
payload
destroy
target
cell
question
includ
radioact
ligand
cytokin
toxin
liposom
contain
drug
specif
killer
cell
type
immunoconjug
defin
antibodi
link
second
molecul
toxin
radioisotop
label
may
act
cell
surfac
kill
agent
intern
releas
payload
intracellularli
despit
high
sensit
reproduc
convent
diagnost
method
microbi
infect
requir
cumbersom
sampl
prepar
long
readout
time
kaittani
et
al
uniqu
electr
magnet
luminesc
catalyt
properti
nanomateri
enabl
fast
sensit
costeffect
diagnosi
well
rapid
determin
suscept
resist
antibacteri
drug
bruchez
et
al
edgar
et
al
antibodyconjug
nanoparticl
amplifi
signal
bioanalysi
enumer
highli
pathogen
bacteria
e
coli
result
highli
select
conveni
rapid
detect
singl
bacterium
within
min
look
et
al
rapid
sensit
determin
pathogen
bacteria
extrem
import
biotechnolog
medic
diagnosi
current
method
either
lack
ultrasensit
take
long
time
analysi
use
magnet
nanoparticl
also
could
sensit
rapid
strategi
detect
microbi
infect
magnet
nanoparticl
particular
superparamagnet
iron
oxid
nanoparticl
spion
appropri
surfac
chemistri
wide
use
experiment
numer
vivo
applic
magnet
reson
imag
contrast
enhanc
tissu
repair
immunoassay
detoxif
biolog
fluid
hyperthermia
drug
deliveri
cell
separ
forth
neuberg
et
al
dextranco
supermagnet
iron
oxid
nanoparticl
cluster
cona
treatment
equip
con
aconjug
nanosensor
zhao
et
al
supermagnet
iron
oxid
nanoprob
greatli
assist
identif
mycobacterium
avium
spp
paratuberculosi
well
quick
quantif
bacteria
milk
blood
high
sensit
basu
et
al
quick
method
detect
infect
urinari
tract
also
develop
use
gold
nanowir
array
conjunct
linker
arm
attach
specif
e
coli
antibodi
de
la
li
huang
shown
nanoparticl
specif
raman
spectroscop
fingerprint
distinguish
antibiot
resist
bacteria
detect
singlenucleotid
polymorph
microarraybas
system
bioassay
base
bioconjug
nanoparticl
develop
zhao
et
al
situ
pathogen
quantif
detect
carri
high
fluoresc
signal
provid
nanoparticl
easili
attach
antibodi
biorecognit
molecul
conjug
nanoparticl
use
specif
identif
wide
rang
bacteria
e
coli
antibodi
antigen
interact
nanoparticl
abl
assess
microbi
metabol
activ
determin
antimicrobi
suscept
blood
rapidli
quantifi
polysaccharid
broad
absorpt
spectra
quantum
dot
qd
exploit
simultan
excit
qd
emit
differ
color
use
singl
wavelength
cao
et
al
charact
suggest
qd
promis
modal
analysi
complex
sampl
histolog
patholog
cytolog
facilit
doubl
even
tripl
immunostain
bacteri
cell
kaittani
et
al
studi
demonstr
use
nanotechnolog
feasibl
achiev
fast
reliabl
pharmaceut
assay
microbi
infect
opaqu
media
eg
whole
blood
milk
without
sampl
prepar
alper
et
al
tulli
et
al
abil
track
distribut
differenti
progenitor
stem
cell
high
resolut
vivo
imag
techniqu
would
signific
clinic
research
implic
lewin
et
al
develop
cell
label
approach
use
short
hivtat
peptid
derivat
superparamagnet
nanoparticl
particl
effici
intern
hematopoiet
neural
progenitor
cell
quantiti
pg
superparamagnet
iron
per
cell
iron
incorpor
affect
cell
viabil
differenti
prolifer
cell
follow
intraven
inject
immunodefici
mice
magnet
cell
home
bone
marrow
per
gram
tissu
singl
cell
could
detect
magnet
reson
imag
tissu
sampl
addit
magnet
label
cell
home
bone
marrow
could
recov
magnet
separ
column
local
retriev
cell
popul
vivo
enabl
detail
analysi
specif
stem
cell
organ
interact
critic
advanc
therapeut
use
stem
cell
lewin
et
al
nanomateri
fluoresc
properti
nanoparticl
labeledencapsul
fluoresc
dye
also
appli
microbi
detect
use
antibodyconjug
silica
nanoparticl
materi
use
superior
signal
element
detect
cell
protein
bacteria
immunoassay
grifantini
et
al
tan
et
al
ultrasensit
method
bioassay
develop
use
fluoresc
bioconjug
silica
nanoparticl
santra
et
al
zhao
et
al
thousand
fluoresc
dye
molecul
encapsul
protect
silica
matrix
result
nanoparticl
amplifi
reproduc
signal
fluorescencebas
bioanalysi
wherea
convent
immunoassay
one
dye
molecul
link
antibodi
molecul
use
signal
antibodyantigen
interact
event
bioconjug
nanoparticl
attach
antibodi
molecul
enabl
carri
mani
dye
molecul
insid
allow
signific
amplif
analyt
signal
furthermor
bacteria
present
mani
surfac
antigen
avail
antibodi
recognit
therefor
greatli
amplifi
signal
achiev
sinc
thousand
nanoparticl
attach
bacterium
bioconjug
nanoparticl
allow
detect
bacterium
cell
per
given
sampl
min
spectrofluoromet
santra
cowork
use
coval
method
attach
surfacemodifi
rubpydop
silica
nanoparticl
mous
antihuman
antibodi
complex
incub
mononuclear
lymphoid
target
cell
wash
away
unbound
nanoparticl
target
leukemia
cell
could
clearli
detect
comparison
control
group
result
experi
shown
techniqu
effect
detect
leukemia
cell
select
santra
et
al
tan
cowork
develop
assay
tool
situ
detect
singl
bacterium
cell
less
min
develop
multicolor
fret
fluoresc
reson
energi
transfer
silica
nanoparticl
coencapsul
three
tandem
dye
emit
uniqu
color
upon
excit
singl
wavelength
among
therapeut
applic
antibodyconjug
nanoparticl
use
gold
nanoparticl
test
kill
staphyloccocu
aureu
zharov
et
al
bacteria
kill
lightadsorb
gold
nanoparticl
conjug
antiprotein
antibodi
use
laser
irradi
nm
protein
chosen
interact
specif
fc
fragment
antibodi
accord
author
kill
effici
depend
local
overh
effect
accompani
bubbleform
phenomena
direct
irradi
bacteria
laser
damag
bacteria
low
absorpt
natur
endogen
cytochrom
diagnosi
cancer
earli
stage
growth
critic
factor
obtain
optim
result
therapi
improv
chanc
surviv
sever
imag
techniqu
collabor
physician
diagnosi
includ
magnet
reson
imag
mri
positron
emiss
tomographi
pet
comput
tomographi
ct
ultrasound
radiographi
photoacoust
imag
fluoroscopi
forth
techniqu
antibodyconjug
nanoparticl
may
offer
increas
select
sensit
fluoresc
semiconductor
nanocryst
qd
novel
class
multifunct
inorgan
fluorophor
promis
biolog
imag
includ
immunofluoresc
imag
wu
use
label
molecul
lidk
et
al
wu
cell
variou
materi
gao
et
al
jaiswal
et
al
kim
even
clinic
human
sampl
tholouli
et
al
first
gener
adc
present
limit
relat
linker
instabl
earli
linker
either
stabl
result
low
potenc
reduc
efficaci
unstabl
result
poor
target
high
system
toxic
furthermor
cytotox
without
suffici
potenc
ineffici
intern
limit
express
target
antigen
immunogen
mab
alley
et
al
chari
secondgener
adc
design
deliv
potent
anticanc
agent
tumor
target
manner
limit
system
exposur
success
target
adc
depend
antibodi
select
potenc
cytotoxin
method
select
link
antibodi
cytotoxin
nanotechnolog
disrupt
technolog
drive
new
gener
cancer
prevent
diagnosi
therapeut
product
result
dramat
improv
cancer
outcom
nanotechnolog
field
cancer
potenti
improv
monitor
therapeut
efficaci
provid
novel
method
detect
profil
cancer
earli
stage
allow
surgeon
delin
tumor
margin
sentinel
lymph
node
nanomateri
uniqu
featur
attract
appli
biosens
develop
variou
nanomateri
nanotechnolog
enabl
detect
cancer
biomark
great
precis
sensit
could
achiev
mani
studi
conduct
develop
sens
mechan
push
detect
limit
far
possibl
anajwala
et
al
ligandfre
nanoformul
gener
possess
passiv
target
properti
littl
tissu
specif
address
limit
research
continu
advanc
activ
specif
target
enhanc
efficaci
anticanc
therapeut
agent
well
reduc
toxic
nontarget
healthi
tissu
nanoparticl
contain
chemotherapeut
agent
specif
design
target
cancer
cell
either
ligand
receptor
interact
antibodyantigen
recognit
highli
specif
mab
use
strengthen
immun
respons
intensifi
immun
system
antitumor
capac
moreov
mab
highli
specif
attach
nanoparticl
aid
target
deliveri
variou
antitumor
cytotox
agent
function
effect
therapeut
agent
sutradhar
amin
differ
way
destroy
cancer
cell
mab
directli
induc
apoptosi
block
growth
factor
receptor
induc
format
antiidiotyp
indirectli
activ
complementmedi
cellular
cytotox
antibodi
depend
cellmedi
cytotox
paramagnet
properti
ironoxid
nanoparticl
har
therapeut
imag
applic
mccarthi
et
al
chen
et
al
report
dextranco
ironoxid
nanoparticl
conjug
radiolabel
iodin
isotop
antivegf
mab
significantli
increas
imag
resolut
well
destruct
liver
cancer
mice
chen
et
al
srinivasan
lakshmikuttyamma
shoyel
srinivasan
et
al
studi
select
target
mab
oncoprotein
cancer
cell
avoid
accumul
normal
cell
result
fluoresc
microscopi
tem
flow
cytometri
reveal
bevacizumab
nanoparticl
intern
cell
time
cell
macropinocytosi
energydepend
pathway
elucid
involv
uptak
cell
studi
present
first
evid
uncoat
mab
nanoparticl
select
deliv
cancer
cell
avoid
normal
cell
mab
also
employ
effect
activ
target
therapi
sinc
antibodi
specif
recogn
overexpress
posit
tumor
cell
intern
receptor
mediat
endocytosi
treat
posit
breast
cancer
human
mab
commonli
use
although
advanc
made
target
cellular
local
via
conjug
strategi
nanoparticul
system
focus
surfac
modifi
ligandreceptormedi
nanotherapi
target
tumor
cell
molecular
level
variou
nanoparticl
system
liposom
micel
dendrim
studi
vitro
also
vivo
conclud
presenc
receptor
target
antibodi
nanocarri
demonstr
higher
toxic
nanocarri
without
antibodi
time
depend
incub
hamidreza
montazeri
et
al
matsumura
yokoyama
antibodi
cell
surfac
biomark
commonli
use
ligand
develop
target
nanoparticl
although
mous
mab
use
make
target
nanoparticl
strong
crossspeci
immun
respons
limit
potenti
futur
clinic
translat
current
type
human
mab
antibodi
herceptin
avail
product
target
nanoparticl
slamon
pegram
altern
high
affin
recombin
antibodi
fragment
develop
target
ligand
yang
et
al
exampl
human
singl
chain
antibodi
epiderm
growth
factor
receptor
scfvegfr
highli
express
major
epitheli
tumor
conjug
differ
type
nanoparticl
specif
tumor
imag
target
therapeut
effect
nanoparticl
demonstr
sever
anim
tumor
model
yang
et
al
major
advantag
use
natur
ligand
tumor
target
high
bind
affin
specif
importantli
low
immunogen
owen
et
al
report
higher
antibodyconjug
lysosom
p
lacotmcc
gpegfuran
micellar
concentr
posit
cell
line
signific
cellular
distribut
result
twoto
threefold
increas
lysosom
accumul
compar
use
antibodi
alon
owen
et
al
addit
nob
et
al
report
thiol
function
mab
conjug
maleimid
contain
liposom
intern
antibodi
coupl
immunoliposom
posit
breast
cancer
cell
line
observ
enhanc
effect
compar
control
liposom
nob
et
al
mani
author
observ
use
lisposom
effect
vitro
vivo
prove
target
drugload
liposom
effect
safe
treatment
option
posit
breast
cancer
vivo
studi
need
conduct
use
mab
conjug
dendrim
result
effect
deliveri
target
overexpress
receptor
tumor
cell
anim
model
recent
miyano
et
al
develop
biocompat
sixth
gener
anion
lysin
amino
acid
dendrim
surfac
modifi
glutam
thereaft
glutam
modifi
lysin
dendrim
coupl
trastuzumab
mab
fluoresc
label
follow
whole
conjug
formul
evalu
posit
neg
cell
line
assess
target
effici
cellular
intern
compar
free
antibodi
applic
result
studi
reveal
high
bind
affin
low
cytotox
cellular
intern
lysosom
traffick
posit
cell
dosedepend
profil
compar
neg
cell
miyano
et
al
subsequ
studi
chen
et
al
gao
et
al
model
protein
toxin
use
develop
antibodi
function
load
plga
nanoparticl
util
two
phase
carbodiimid
process
modifi
encapsul
nanoparticl
show
higher
vitro
cytotox
protect
antitumor
activ
compar
control
overexpress
cell
tumorbear
mice
respect
addit
report
well
toler
maximum
toler
dose
well
reduc
system
toxic
modifi
nanoparticl
administ
mice
model
compar
control
chen
et
al
gao
et
al
nanotechnolog
promot
greater
opportun
higher
specif
drug
deliveri
minimum
side
effect
bioconjug
strategi
therapeut
agent
load
nanoparticl
mab
exhibit
target
drug
deliveri
approach
vitro
vivo
mab
act
highli
specif
probe
attach
nanoparticl
aid
target
deliveri
variou
antitumor
cytotox
agent
sutradhar
amin
combin
therapi
nanopartilc
mab
chemotherapeut
agent
doxorubicin
paclitaxel
docetaxel
campothecin
topotecan
could
bring
synergist
tumor
growth
inhibit
nanoparticul
system
combin
antibodi
chemotherapeut
agent
list
tabl
neovascular
major
caus
visual
loss
number
ophthalm
diseas
consist
new
blood
vessel
growth
preexist
vascular
structur
process
occur
patholog
anterior
posterior
segment
eye
corneal
neovascular
agerel
macular
degener
amd
diabet
macular
edema
viral
retin
prolif
vitreoretinopathi
posterior
uveiti
retin
vascular
occlus
choroid
neovascular
cnv
diabet
retinopathi
name
antivegf
agent
demonstr
efficaci
reduc
neovascular
anim
model
clinic
trial
specif
antivegf
antibodi
shown
initi
therapeut
success
bevacizumab
fulllength
human
murin
mab
recogn
isoform
vegf
bevacizumab
initi
approv
us
food
drug
administr
fda
treat
metastat
colon
cancer
also
shown
efficaci
treatment
variou
neovascular
ocular
diseas
use
offlabel
treat
neovascular
agerel
macular
degener
topic
deliveri
rel
easi
less
riski
method
drug
administr
howev
deliveri
posterior
segment
via
rout
consid
ineffici
unsuccess
sinc
less
topic
appli
dose
enter
eye
even
smaller
fraction
expect
reach
posterior
segment
intravitr
administr
involv
direct
administr
drug
solutionsuspens
vitreou
humor
via
par
plana
use
needl
contrast
topic
roth
et
al
system
rout
intravitr
inject
make
high
concentr
drug
local
avail
intern
eye
tissu
includ
choroid
retina
similarli
intravitr
administr
macugen
pegaptanib
sodium
pfizer
lucenti
ranibizumab
genentechnovarti
vascular
endotheli
growth
factor
vegf
inhibitor
highli
success
control
amd
howev
agent
molecular
weight
less
da
appli
intravitr
tend
drain
site
applic
halflif
less
day
indic
need
repetit
inject
anyway
period
requir
repeat
dose
may
extend
day
sever
month
macromolecular
antibodi
exampl
three
mean
number
inject
bevacizumab
avastin
roch
requir
administ
per
year
treatment
amd
hand
recommend
dose
frequenc
ranibizumab
lucenti
month
mg
least
month
rosenfeld
et
al
wherea
pegaptanib
sodium
macugen
need
inject
intravitr
interv
year
kitagawa
yuzawa
nevertheless
repetit
intravitr
inject
even
space
wide
invari
associ
complic
vitreou
hemorrhag
retin
detach
cataract
endophthalm
rate
endophthalm
retin
detach
observ
intravitr
inject
respect
edelhaus
et
al
moreov
patient
complianc
lower
regimen
pain
invas
procedur
requir
hospit
special
train
physician
administr
addit
high
cost
medicin
per
se
kaur
kakkar
biodegrad
polymer
nanoparticl
offer
properti
make
suitabl
candid
overcom
administr
issu
regard
abrishami
et
al
studi
encapsul
bevacizumab
liposomesand
found
intravitr
inject
liposom
well
toler
day
rabbit
clearanc
drug
vitreou
liposom
formul
slower
solubl
form
concentr
level
bevacizumab
intravitr
inject
suggest
intravitr
inject
drug
carrier
provid
suffici
concentr
therapeut
drug
week
diabet
neovascular
probabl
neovascular
eye
diseas
abrishami
et
al
author
develop
nanoparticl
plga
load
bevacizumab
stabil
whit
albumin
found
vitreou
concentr
bevacizumab
sustain
week
valu
greater
ng
ml
nanoparticl
present
drug
vitreou
medium
retent
time
mrt
time
higher
control
addit
confirm
nanoparticl
persist
ocular
tissu
day
varshochian
et
al
varshochian
et
al
recent
lu
et
al
studi
effect
intravitr
inject
bevacizumabchitosan
nanoparticl
patholog
morpholog
retina
express
vascular
endotheli
growth
factor
vegf
protein
vegf
mrna
retina
diabet
rat
result
offer
new
approach
inhibit
angiogenesi
diabet
retinopathi
indic
intravitr
inject
bevacizumab
inhibit
vegf
express
retina
addit
bevacizumabchitosan
nanoparticl
present
longer
period
action
zhou
et
al
chronic
respiratori
diseas
crd
chronic
diseas
airway
structur
lung
among
common
asthma
chronic
obstruct
pulmonari
diseas
copd
respiratori
allergi
mention
airway
inflamm
diseas
alway
control
convent
therapi
critic
role
combin
therapi
inhal
corticosteroid
ic
longact
agonist
laba
treatment
patient
also
suffer
sever
asthma
chronic
obstruct
pulmonari
diseas
copd
explain
strong
interest
within
pharmaceut
industri
develop
new
pharmaceut
altern
biolog
therapi
repres
particular
mab
select
target
could
improv
outcom
diseas
mani
current
public
shown
import
role
nanomedicin
treatment
respiratori
diseas
card
et
al
mansour
et
al
smola
et
al
system
releas
nanoparticl
sever
possibl
improv
treatment
upper
respiratori
tract
sinc
protect
drug
degrad
enzym
present
epitheli
line
fluid
particl
size
may
permit
circumv
pass
macrophag
cross
endothelium
allow
system
treatment
nanoparticl
pulmonari
drug
intraven
administr
identifi
asthma
phenotyp
given
impetu
search
biomark
help
classifi
patient
point
new
therapi
predict
differ
patholog
mechan
diseas
progress
strong
benefit
affect
patient
ideal
biomark
easi
detect
measur
noninvas
inexpens
use
identifi
phenotyp
either
clinic
respons
treatment
assess
chang
diseas
activ
confirm
diagnosi
copd
current
fourth
lead
caus
death
world
current
trend
continu
like
rank
third
lead
caus
death
world
health
organ
cytokin
chemokin
play
fundament
role
organ
copd
use
mab
treatment
option
valuabl
provid
target
therapi
li
et
al
yamagata
ichinos
numer
antibodi
direct
cytokin
chemokin
growth
factor
receptor
consid
treatment
copd
alreadi
studi
clinic
trial
patient
copd
macrophag
imag
use
mri
togeth
use
magnet
nanoparticl
iron
oxid
recent
emerg
promis
noninvas
techniqu
preclin
clinic
studi
inflammatori
diseas
howev
limit
research
inflamm
passag
macrophag
lung
use
imag
technolog
perform
due
difficulti
imag
bodi
ie
signal
loss
due
pulsat
heart
breath
low
proton
densiti
suscept
artifact
novel
perspect
imag
diagnosi
treatment
respiratori
diseas
copd
appear
due
technic
improv
develop
techniqu
magnet
reson
puls
sequenc
detect
studi
report
possibl
noninvas
monitor
subset
macrophag
inflammatori
model
use
high
resolut
mri
intraven
administr
possibl
noninvas
monitor
subset
macrophag
report
inflammatori
model
use
high
resolut
mri
intraven
administr
furthermor
studi
proven
polar
prolifer
affect
use
iron
oxid
nanoparticl
ex
vivo
label
subpopul
macrophag
coupl
specif
antibodi
iron
oxid
nanoparticl
direct
particular
subpopul
macrophag
may
provid
promis
strategi
earli
diagnosi
improv
variou
inflammatori
diseas
noninvas
use
mri
al
faraj
et
al
evalu
vivo
effect
intrapulmonari
administr
spion
profil
alveolar
macrophag
polar
model
copd
develop
protocol
mri
noninvas
specif
target
monitor
subpopul
macrophag
use
specif
antibodyconjug
spion
interest
approach
perform
target
subpopul
macrophag
lung
copd
anim
model
use
biocompat
antibodyconjug
iron
oxid
nanoparticl
conjug
allow
noninvas
track
use
freebreath
mri
protocol
antibodi
abgenix
improv
dyspnea
lung
function
limit
clinic
benefit
attribut
suboptim
dose
airway
intraven
administr
mahler
et
al
therefor
use
nanoparticl
may
allow
administr
inhal
local
concentr
avoid
side
effect
far
clinic
trial
antitnfalpha
antibodi
infliximab
carri
effect
patient
copd
observ
denten
et
al
rennard
et
al
van
der
vaart
et
al
therefor
releas
cetuximab
current
undergo
clinic
trial
cancer
therapi
could
valuabl
option
treatment
copd
molecularli
target
nanoparticl
chosen
best
strategi
imag
inflamm
make
progress
health
care
mccarthi
weissled
weissled
magnet
nanoparticl
versatil
make
well
suit
applic
enabl
earli
detect
prevent
improv
diagnosi
treatment
followup
diseas
oghabian
farahbakhsh
al
faraj
et
al
develop
assay
quantifi
antibodi
conjug
spion
involv
reduct
cu
cu
protein
appear
purpleblu
copperprotein
complex
alkalin
medium
signific
trend
appear
develop
includ
bispecif
antibodi
adc
companion
diagnost
help
identifi
appropri
patient
popul
treatment
even
though
health
benefit
mab
therapeut
proven
controversi
continu
econom
viabil
expens
price
high
price
howev
gener
associ
earli
innov
treatment
mab
drug
stagger
price
cost
cancer
treatment
exampl
doubl
past
two
decad
lead
outcri
mani
european
american
cancer
specialist
anoth
reason
mab
expens
fact
mani
still
protect
patent
drug
patent
life
year
date
file
order
help
develop
recov
research
develop
cost
involv
get
drug
market
patent
life
fact
reduc
time
averag
year
taken
clinic
trial
regulatori
approv
siddiqui
rajkumar
slow
progress
mab
therapeut
infecti
diseas
attribut
part
larg
arsen
antiinfect
drug
vaccin
antibiot
specif
singl
pathogen
mab
drug
also
commerci
less
attract
tradit
drug
cover
narrow
spectrum
patient
addit
mab
need
administ
intraven
subcutan
inject
unlik
antiinfect
taken
oral
unsuit
patient
develop
countri
limit
access
healthcar
mab
also
effect
prevent
infect
rather
treat
establish
one
unlik
vaccin
provid
shortterm
prophylaxi
final
high
develop
manufactur
cost
associ
mab
poor
record
win
approv
treat
infecti
diseas
mab
lessen
commerci
appeal
reichert
promis
recent
develop
enhanc
potenc
efficaci
mab
make
possibl
prescrib
lower
dose
potenti
reduc
cost
number
approach
adopt
augment
efficaci
mab
one
encourag
use
genet
engin
remov
glycosyl
site
variabl
domain
antibodi
enhanc
effector
function
mab
antibodydepend
cellmedi
cytotox
adcc
activ
patient
innat
immun
cell
kill
target
cell
like
cancer
although
new
gener
mab
may
greatli
improv
treatment
cancer
autoimmun
disord
wellestablish
diseas
target
mab
therapeut
remain
seen
whether
mab
therapeut
effect
area
nowher
question
urgent
case
infecti
diseas
fact
mab
therapeut
pathogenspecif
could
hinder
use
treat
mix
infect
one
solut
might
lie
use
cocktail
mab
target
divers
rang
antigen
virus
carri
strategi
would
effect
mimic
natur
immun
respons
infect
bodi
tend
develop
sever
antibodi
respons
antigen
present
viru
attach
one
differ
antigen
divers
antibodi
help
immun
system
fight
invad
use
cocktail
mab
alreadi
investig
treatment
rabi
recent
advanc
mab
engin
open
new
opportun
serum
therapi
importantli
mab
offer
mean
prepar
standard
agent
combin
cocktail
yield
product
precis
potent
tradit
serum
therapi
date
develop
antiinfect
mab
product
attract
littl
commerci
invest
part
infecti
diseas
shortliv
therefor
limit
market
contrast
chronic
condit
like
cancer
autoimmun
diseas
requir
regular
treatment
therefor
greater
profit
potenti
nonetheless
pharmaceut
climat
chang
fuel
concern
rise
new
pathogen
west
nile
corona
virus
reemerg
old
pathogen
like
tuberculosi
increas
antibiot
resist
among
microorgan
rise
superbug
like
mrsa
well
grow
epidem
patient
immunocompromis
result
hiv
infect
organ
transplant
chronic
degen
diseas
improv
cancer
care
likewis
mab
use
investig
treat
cancer
provid
power
tool
identifi
target
differ
antigen
tumor
although
applic
quickli
translat
success
mab
therapeut
cancer
recent
year
mab
therapeut
offer
altern
drug
broad
spectrum
high
toxic
transform
care
cancer
patient
longer
face
prospect
lose
hair
seriou
side
effect
associ
cytotox
drug
advantag
mab
given
mainten
therapi
reshap
percept
cancer
seen
inevit
fatal
chronic
condit
mab
also
enabl
prescript
specif
therapeut
particular
tumor
antigen
individu
patient
allow
greater
degre
person
manag
cancer
past
inde
mab
expect
increasingli
import
compon
person
cancer
therapi
world
antibioticresist
superbug
age
popul
grappl
autoimmun
disord
cancer
mab
offer
potenti
new
target
treatment
drug
offer
person
careand
window
complex
overlap
condit
underli
human
diseas
